论文部分内容阅读
Bricef一般叫羟氨唑头孢菌素(Cefatr izine以下简称CFT),是美国Bristol研究所研制的。它广泛作用于革兰氏阳性菌及革兰氏阴性菌,其抗菌效力是先锋霉素Ⅳ的2～8-倍。文章总结了该药治疗齿科各种感染的临床效果和副作用。临床资料:治疗98例,均为齿科门诊患者,男性46名,女性52名,年龄15～73岁,急性牙槽骨炎29例,急性智齿冠周炎25例,急性颌骨骨膜炎24例,边缘性牙周炎急性发作11例,皮下脓肿3例,急性上颌窦炎2例,急性坏死性口腔炎2例,慢性颌骨骨髓炎1例,急性淋巴结炎1例。其中2例因为出现副作用中止投药,无法判定效果。
Bricef commonly called cefotaxime (Cefatr izine hereinafter referred to as CFT), is the United States Bristol Institute developed. It is widely used in Gram-positive bacteria and Gram-negative bacteria, its antibacterial efficacy is 2-8 times that of cephalosporins. The article summarizes the clinical effects and side effects of the drug in the treatment of various dental infections. Clinical data: Treatment of 98 cases, all outpatients, 46 males and 52 females, aged 15 to 73 years, 29 cases of acute alveolar osteosynthesis, acute pericoronitis in 25 cases, acute pericarditis 24 Cases, 11 cases of acute marginal periodontitis, subcutaneous abscess in 3 cases, 2 cases of acute maxillary sinusitis, acute necrotizing stomatitis in 2 cases, 1 case of chronic jaw osteomyelitis, 1 case of acute lymphadenitis. Two of them discontinued administration due to side effects and were unable to determine the effect.